中國生物製藥(01177.HK)盈喜:上半年歸母淨利預增超500%
格隆匯8月18日丨中國生物製藥(01177.HK)發佈公吿,預期集團截至2021年6月30日止六個月期間的歸屬於母公司持有者應占盈利較去年同期增長超過500%(去年同期歸屬於母公司持有者應占盈利(重列)為人民幣124,061萬元)。
公吿表示,歸屬於母公司持有者應占盈利同比大幅增長主要受惠於:(1)集團主營業務表現令人滿意。期內新產品、高毛利率產品銷售佔比上升,集團收入及毛利率雙雙同比明顯提升;及(2)聯營公司財務表現強勁,集團期內應占聯營公司及合營公司盈虧同比大幅增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.